← boardnext 2026-08-25next 2028-02
CLRB
Cellectar Biosciences, Inc.distress 10/10 · high distress / dilution risk$2.460%today-60% from 52w high
Oncology 3
Lead: solid tumor cancers
Revenue
pre-revenue
Liquidity
$8M
Runway
0.5 yrs
Shares 1y
+150%
Price & events
-35.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
-4.7%
1W
-1.6%
1M
-11.8%
3M
-35.1%
6M
-56.0%
1Y
-96.7%
2Y
-99.3%
5Y
-99.6%
All
Overview
- Market Cap
- $19.66M
- Volume
- 7.84K
- 52 Week Range
- $2.23 – $6.17
- Total Shares
- 7.99M
- Float Shares
- 7.82M
- Short %
- 2.44%
- % Held by Insiders
- 2.07%
- % Held by Institutions
- 16.62%
- RVOL
- 0.07x
- Beta
- 0.55
Pipeline stages · 2 programs
CLR 131
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Iopofosine I 131, CLR 125
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-25 Estimated 50% readout ~2026-09-24 final ~2027-02-28 | Phase 1 | CLR 131 | Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma | 30 | active not recruiting |
| 2028-02 Estimated 50% readout ~2028-03-02 | Phase 1 | Iopofosine I 131, CLR 125breakthroughorphanrare pediatricfast track | Breast Cancer | — | recruiting |
| 2026-06-22 | Phase 2 | Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionatebreakthroughorphanrare pediatricfast track | Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma | 120 | active not recruiting |
| 2026-05 | Phase 1 | CLR 131 | High-Grade Glioma | 50 | active not recruiting |
Catalyst news & presentations · 7
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- early 2026regulatory submissionFiled (NDA/BLA)iopofosine I 131 · Submit CMA application to EMASEC 8-K
- second half of 2025trial initiationsecondaryPhase 1CLR 225 · Phase 1 imaging and dose escalation safety studySEC 8-K
- 2025-10-06fda agreementiopofosine I 131 · SAWP confirmed eligibility to file for CMA for iopofosine I 131 in post-BTKi refractory WMSEC 8-K
- first half of 2025trial initiationsecondaryPhase 1CLR 121225 · IND filing expected H1 2025 to initiate Phase 1 studySEC 8-K
- first quarter of 2025regulatory submissionFiled (NDA/BLA)CLR 121225 · Plans to file IND for alpha-emitting radioconjugateSEC 8-K
- 2024-08-20withdrawalReceived Nasdaq delinquency notice for failure to file Q2 2024 10-Q on timeSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $12 (+367% upside) · 4 analysts
- 2026-03-10Maxim GroupHold → Buy
- 2025-05-14Maxim GroupBuy → Hold
- 2024-12-11OppenheimerOutperform → Perform
- 2024-11-19OppenheimerOutperform
Competitors — solid tumor cancers
- none identified
Recent news
- 2026-07-22Cellectar Biosciences (CLRB) Proxy filing Summary - Quartr
- 2026-07-22Cellectar Biosciences (CLRB) Q1 2026 earnings summary - Quartr
- 2026-07-22Cellectar Biosciences (CLRB) Q4 2025 earnings summary - Quartr
- 2026-07-22Cellectar Biosciences (CLRB) Proxy filing Summary - Quartr
- 2026-07-22Cellectar Biosciences (CLRB) Registration filing Summary - Quartr
- 2026-07-22Cellectar Biosciences (CLRB) Proxy filing Summary - Quartr
- 2026-07-21Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia - Bitget
- 2026-07-15Cellectar Biosciences (CLRB) Announces Positive Phase 1 Study Re - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.